336 related articles for article (PubMed ID: 18765093)
1. Mineralocorticoid antagonism and cardiac hypertrophy.
Nagata K
Curr Hypertens Rep; 2008 Jun; 10(3):216-21. PubMed ID: 18765093
[TBL] [Abstract][Full Text] [Related]
2. Mineralocorticoid receptor antagonism attenuates cardiac hypertrophy and failure in low-aldosterone hypertensive rats.
Nagata K; Obata K; Xu J; Ichihara S; Noda A; Kimata H; Kato T; Izawa H; Murohara T; Yokota M
Hypertension; 2006 Apr; 47(4):656-64. PubMed ID: 16505208
[TBL] [Abstract][Full Text] [Related]
3. Vascular Consequences of Aldosterone Excess and Mineralocorticoid Receptor Antagonism.
Chrissobolis S
Curr Hypertens Rev; 2017; 13(1):46-56. PubMed ID: 28245785
[TBL] [Abstract][Full Text] [Related]
4. Aldosterone: role in the cardiometabolic syndrome and resistant hypertension.
Whaley-Connell A; Johnson MS; Sowers JR
Prog Cardiovasc Dis; 2010; 52(5):401-9. PubMed ID: 20226958
[TBL] [Abstract][Full Text] [Related]
5. Effects of salt status and blockade of mineralocorticoid receptors on aldosterone-induced cardiac injury.
Hattori T; Murase T; Sugiura Y; Nagasawa K; Takahashi K; Ohtake M; Ohtake M; Miyachi M; Murohara T; Nagata K
Hypertens Res; 2014 Feb; 37(2):125-33. PubMed ID: 24048492
[TBL] [Abstract][Full Text] [Related]
6. Hypertension: renin-angiotensin-aldosterone system alterations.
Te Riet L; van Esch JH; Roks AJ; van den Meiracker AH; Danser AH
Circ Res; 2015 Mar; 116(6):960-75. PubMed ID: 25767283
[TBL] [Abstract][Full Text] [Related]
7. The pharmacological treatment of primary aldosteronism.
Janmohamed S; Bouloux PM
Expert Opin Pharmacother; 2006 Apr; 7(5):563-73. PubMed ID: 16553572
[TBL] [Abstract][Full Text] [Related]
8. Pharmacological treatment of aldosterone excess.
Deinum J; Riksen NP; Lenders JW
Pharmacol Ther; 2015 Oct; 154():120-33. PubMed ID: 26213109
[TBL] [Abstract][Full Text] [Related]
9. Aldosterone receptor antagonists: current perspectives and therapies.
Guichard JL; Clark D; Calhoun DA; Ahmed MI
Vasc Health Risk Manag; 2013; 9():321-31. PubMed ID: 23836977
[TBL] [Abstract][Full Text] [Related]
10. The Role of Aldosterone in Obesity-Related Hypertension.
Kawarazaki W; Fujita T
Am J Hypertens; 2016 Apr; 29(4):415-23. PubMed ID: 26927805
[TBL] [Abstract][Full Text] [Related]
11. Aldosterone and the risk of hypertension.
Xanthakis V; Vasan RS
Curr Hypertens Rep; 2013 Apr; 15(2):102-7. PubMed ID: 23378101
[TBL] [Abstract][Full Text] [Related]
12. Aldosterone and refractory hypertension.
Nyirenda MJ; Padfield PL
Curr Opin Endocrinol Diabetes Obes; 2007 Jun; 14(3):213-8. PubMed ID: 17940442
[TBL] [Abstract][Full Text] [Related]
13. Treatment of Resistant and Refractory Hypertension.
Acelajado MC; Hughes ZH; Oparil S; Calhoun DA
Circ Res; 2019 Mar; 124(7):1061-1070. PubMed ID: 30920924
[TBL] [Abstract][Full Text] [Related]
14. Effects of aldosterone and angiotensin II receptor blockade on cardiac angiotensinogen and angiotensin-converting enzyme 2 expression in Dahl salt-sensitive hypertensive rats.
Takeda Y; Zhu A; Yoneda T; Usukura M; Takata H; Yamagishi M
Am J Hypertens; 2007 Oct; 20(10):1119-24. PubMed ID: 17903697
[TBL] [Abstract][Full Text] [Related]
15. The endothelin-aldosterone axis and cardiovascular diseases.
Rossi GP; Cavallin M; Nussdorfer GG; Pessina AC
J Cardiovasc Pharmacol; 2001 Nov; 38 Suppl 2():S49-52. PubMed ID: 11811378
[TBL] [Abstract][Full Text] [Related]
16. Aldosterone and parathyroid hormone interactions as mediators of metabolic and cardiovascular disease.
Tomaschitz A; Ritz E; Pieske B; Rus-Machan J; Kienreich K; Verheyen N; Gaksch M; Grübler M; Fahrleitner-Pammer A; Mrak P; Toplak H; Kraigher-Krainer E; März W; Pilz S
Metabolism; 2014 Jan; 63(1):20-31. PubMed ID: 24095631
[TBL] [Abstract][Full Text] [Related]
17. Galectin-3 blockade inhibits cardiac inflammation and fibrosis in experimental hyperaldosteronism and hypertension.
Martínez-Martínez E; Calvier L; Fernández-Celis A; Rousseau E; Jurado-López R; Rossoni LV; Jaisser F; Zannad F; Rossignol P; Cachofeiro V; López-Andrés N
Hypertension; 2015 Oct; 66(4):767-75. PubMed ID: 26238446
[TBL] [Abstract][Full Text] [Related]
18. Primary aldosteronism: considerations about the evaluation of the aldosterone to renin ratio during canrenone treatment.
Armanini D; Sabbadin C; Boscaro M
J Endocrinol Invest; 2021 Sep; 44(9):2009-2010. PubMed ID: 33454931
[No Abstract] [Full Text] [Related]
19. Renin Phenotypes Characterize Vascular Disease, Autonomous Aldosteronism, and Mineralocorticoid Receptor Activity.
Hundemer GL; Baudrand R; Brown JM; Curhan G; Williams GH; Vaidya A
J Clin Endocrinol Metab; 2017 Jun; 102(6):1835-1843. PubMed ID: 28323995
[TBL] [Abstract][Full Text] [Related]
20. Unilateral primary aldosteronism with spontaneous remission after long-term spironolactone therapy.
Yoneda T; Demura M; Takata H; Kometani M; Karashima S; Yamagishi M; Takeda Y
J Clin Endocrinol Metab; 2012 Apr; 97(4):1109-13. PubMed ID: 22337911
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
